Alexis Boro, MD
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,002 of the $2,551 with a category attached, or 78.5%. 4 manufacturers reported payments, led by Neuropace, Inc. at 52.8% of the total. Reporting peaked in 2019 at $2,492 and has fallen 99.1% since, to $22 in 2024.
Across 17 payments — averaging $150.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$1K
- UCB SA$1K
- Livanova USA, Inc.$36
- SK Life Science, Inc.$22
Across 93 payments — averaging $4285.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$144K
- SK Life Science, Inc.$127K
- UCB SA$127K
What the payments were for
- Travel & lodging$2,00278%
- Food & beverage$54922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 4 | $1,346 |
| UCB SA | 10 | $1,147 |
| Livanova USA, Inc. | 2 | $36 |
| SK Life Science, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS System$1,281
How this compares
$2,551 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 140 | $236,077 |
| BriviactBrivaracetam | 63 | $88,484 |
| EpidiolexCannabidiol (Cbd) | 13 | $54,723 |
| AptiomEslicarbazepine Acetate | 16 | $35,938 |
| KeppraLevetiracetam | 15 | $28,439 |
| FycompaPerampanel | 19 | $20,567 |
| Lacosamide | 191 | $18,299 |
| Clobazam | 101 | $17,130 |
| VimpatLacosamide | 15 | $17,009 |
| ValtocoDiazepam | 11 | $8,718 |
| Lamotrigine ErLamotrigine | 15 | $8,253 |
| Carbamazepine ErCarbamazepine | 118 | $7,747 |
| Topiramate | 21 | $7,678 |
| Levetiracetam | 266 | $7,377 |
| KlonopinClonazepam | 11 | $3,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $22 | $236,077140 claims |
| UCB SAKeppra | $1,147 | $28,43915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.
Other neurology in Bronx
- Richard LiptonBronx$753K
- Michael ThorpyBronx$232K
- Rene ElkinBronx$186K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.